Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | REN | P00797 | 3/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23275569 | 1.00 | CTSK (0.59) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL23275571 | 1.00 | CTSK (0.59) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL7850315 | 0.93 | CTSK (0.62) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL22117446 | 0.92 | CTSK (0.57) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL22117444 | 0.92 | CTSK (0.57) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL5966543 | 0.92 | CTSK (0.57) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL5966551 | 0.92 | CTSK (0.57) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL22117445 | 0.92 | CTSK (0.57) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL31075598 | 0.90 | REN (0.50) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL18099941 | 0.90 | CTSS (0.64) | CTSKCTSSCTSBCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | CTSK 1406/4885CTSS 3558/4885CTSB 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.